ZYTONOVA
LIVE

Serial Number

79368062

Owner

ZytoVision GmbH

Attorney

Laurence P. Colton

Filing Date

Nov 17, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ZYTONOVA Trademark

Serial Number: 79368062 • Registration: 7383469

ZYTONOVA is a trademark filed by ZytoVision GmbH on November 17, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

ZytoVision GmbH (6 trademarks)

Fischkai 1

Entity Type: 99

Trademark Details

Filing Date

November 17, 2022

Registration Date

May 14, 2024

Published for Opposition

February 27, 2024

Goods & Services

Science and technology services, namely, research and design in the field of genetic analyses including analyses of genetic alterations in tumors; medical laboratory services; medical research laboratory services; development of pharmaceutical preparations and medicines; clinical research, namely conducting clinical trials for others; research relating to biotechnology; scientific consultancy services relating to hazardous materials management; biological analysis, biochemical analysis, chemical analysis, scientific analysis, namely, dna, rna, and protein analysis services for scientific research purposes; scientific research in the field of genetics and genetic engineering

Business management consultancy and advisory services; operation of businesses for others, namely biotechnological and medical companies; running of a holding company performed for third parties, namely business management, business administration, and providing office functions; holding company services performed for third parties, namely, development of marketing strategy, business management and business management consultation; business management and organization consultation; advisory services relating to business management; business administration; providing office functions; business development services, namely, planning and monitoring of business developments and organizational services for business purposes

Research laboratory analyzers for measuring, testing and analyzing blood and other bodily fluids; analysis apparatus, namely, research laboratory analyzers, for measuring, testing and examining tissue, cells and biomolecules including dna, rna and proteins

Medical analytical apparatus for medical purposes, namely, medical diagnostic instruments for the analysis of dna, rna and proteins; automatic analyzers for medical diagnosis, namely, medical diagnostic instruments for the analysis of body fluids and tissues; genetic testing apparatus for medical purposes

Medical services; medical diagnostic services, namely, medical testing for diagnostic or treatment purposes; in-vitro analysis for medical and pharmaceutical use, namely, medical services in the field of genetic disorders including genetic aberrations in tumors; medical services using the knowledge in the field of pathology, genetic science, human genetics, molecular pathologies, molecular biology, microbiology, biotechnology and laboratory medicine; medical services by means of histology, cytology, immunohistology, immunohistochemistry, in situ hybridization, pcr (polymerase chain reaction), ngs (next generation sequencing), microarray hybridization (genetic chip or biochip hybridization), flow cytometry and isolation of biomolecules including DNA, RNA and proteins; medical counseling; pharmaceutical compounding services; pharmaceutical advice; medical and healthcare services relating to dna, genetics and genetic testing; medical pathology services, namely pathology diagnostic services; genetic testing for medical purposes

Chemicals for use in industry and science; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; biochemicals, namely, polynucleotides, oligonucleotides, peptides, proteins, enzymes, and antibodies for in vitro scientific and research purposes; chemicals and biochemicals, namely, nucleic acids and antibodies for use in the detection of genetic alterations, other than for medical or veterinary purposes; nucleic acids and antibodies for laboratory use; chemicals for use in industry and science, namely, dna probes, rna probes and oligonucleotide probes being biochemical substances, antibodies, enzymes, and oligonucleotides for carrying out molecular biological processes; mixtures of chemical reagents in kit form, other than for medical or veterinary purposes, namely, kits for scientific purposes consisting primarily of chemical reagents

Medical preparations, namely, medical diagnostic reagents for diagnosis of genetic disorders; medical preparations for diagnostics, namely, medical diagnostic reagents for diagnosis of genetic aberrations in tumors; medical preparations for in vitro diagnostics, namely, test kits containing antibodies, probes, enzymes, buffers and reagents for diagnosis of genetic disorders including genetic aberrations in tumors; nucleic acids sequences, peptide sequences, and chemical reagents for medical and veterinary purposes; biological and chemical preparations, namely, dna, rna and oligonucleotide probes composed of biochemical substances, oligonucleotides, proteins and enzymes and antibodies, all for medical and veterinary diagnostic purposes; biological and chemical preparations for medical and veterinary purposes, namely, dna probes, rna probes and oligonucleotide probes being polynucleotides, biochemical substances, oligonucleotides, proteins and enzymes and antibodies for diagnosis of genetic disorders including genetic aberrations in tumors; diagnostic biomarker reagents for medical purposes

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 6, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 30, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 9, 2024 FICS
FINAL DISPOSITION PROCESSED
Nov 8, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 14, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 14, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
May 14, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 4, 2024 NPUB
NOTIFICATION PROCESSED BY IB
Feb 27, 2024 GPNX
PUBLISHED FOR OPPOSITION
Feb 27, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 7, 2024 OPNS
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 7, 2024 NPUB
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 7, 2024 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 7, 2024 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 23, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 23, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 22, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jan 22, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 13, 2023 GNFN
FINAL REFUSAL E-MAILED
Dec 13, 2023 GNFR
FINAL REFUSAL WRITTEN
Dec 13, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 10, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 9, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 9, 2023 TROA
REFUSAL PROCESSED BY IB
Oct 17, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 25, 2023 RFCS
REFUSAL PROCESSED BY MPU
Sep 25, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 7, 2023 RFCR
NON-FINAL ACTION WRITTEN
Sep 6, 2023 CNRT
ASSIGNED TO EXAMINER
Aug 30, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 26, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 22, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 20, 2023 REPR